DICE is a CRO with 35 years of experience, having assisted in the execution of over 300 studies from Phase I to IV across a range of therapeutic areas, including oncology, neurology, dermatology, ophthalmology, and orphan diseases, and medical technologies. DICE is specialized in Central Imaging Review, Biostatistics, Clinical Data…
From Idea to Intellectual Property (IP) is what De Clercq & Partners stands for. We help you navigate through the complex and dynamic world of IP, securing optimum protection for your achievements by patents, trademarks, designs and domain names. Together with you, our superb team of over twenty qualified European…
DeuterOncology is a clinical-stage drug development company. Its lead product, DO-2, is a deuterated MET kinase inhibitor that is brain penetrant and is being developed as a potential ‘best in class’ targeted therapy for MET driven disease. MET-inhibitors shows success in NSCLC however these treatments are hindered by the toxic…